Oxyguanidines. Part 2. Discovery of a Novel Orally Active Thrombin Inhibitor Through Structure-Based Drug Design and Parallel Synthesis.

ChemInform ◽  
2004 ◽  
Vol 35 (47) ◽  
Author(s):  
Tianbao Lu ◽  
et al. et al.
2004 ◽  
Vol 14 (14) ◽  
pp. 3727-3731 ◽  
Author(s):  
Tianbao Lu ◽  
Thomas Markotan ◽  
Frank Coppo ◽  
Bruce Tomczuk ◽  
Carl Crysler ◽  
...  

2000 ◽  
Vol 43 (19) ◽  
pp. 3482-3486 ◽  
Author(s):  
Y. Sudhakar Babu ◽  
Pooran Chand ◽  
Shanta Bantia ◽  
Pravin Kotian ◽  
Ali Dehghani ◽  
...  

2000 ◽  
Vol 7 (7) ◽  
pp. 493-504 ◽  
Author(s):  
J Rahuel ◽  
V Rasetti ◽  
J Maibaum ◽  
H Rüeger ◽  
R Göschke ◽  
...  

2019 ◽  
Author(s):  
Mohammad Rezaei ◽  
Yanjun Li ◽  
Xiaolin Li ◽  
Chenglong Li

<b>Introduction:</b> The ability to discriminate among ligands binding to the same protein target in terms of their relative binding affinity lies at the heart of structure-based drug design. Any improvement in the accuracy and reliability of binding affinity prediction methods decreases the discrepancy between experimental and computational results.<br><b>Objectives:</b> The primary objectives were to find the most relevant features affecting binding affinity prediction, least use of manual feature engineering, and improving the reliability of binding affinity prediction using efficient deep learning models by tuning the model hyperparameters.<br><b>Methods:</b> The binding site of target proteins was represented as a grid box around their bound ligand. Both binary and distance-dependent occupancies were examined for how an atom affects its neighbor voxels in this grid. A combination of different features including ANOLEA, ligand elements, and Arpeggio atom types were used to represent the input. An efficient convolutional neural network (CNN) architecture, DeepAtom, was developed, trained and tested on the PDBbind v2016 dataset. Additionally an extended benchmark dataset was compiled to train and evaluate the models.<br><b>Results: </b>The best DeepAtom model showed an improved accuracy in the binding affinity prediction on PDBbind core subset (Pearson’s R=0.83) and is better than the recent state-of-the-art models in this field. In addition when the DeepAtom model was trained on our proposed benchmark dataset, it yields higher correlation compared to the baseline which confirms the value of our model.<br><b>Conclusions:</b> The promising results for the predicted binding affinities is expected to pave the way for embedding deep learning models in virtual screening and rational drug design fields.


Sign in / Sign up

Export Citation Format

Share Document